IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study. Issue 18 (20th April 2022)

• Record Type: Journal Article
• Authors: Robertson, Louise J.; Price, Ruth; Moore, Julie S.; Curry, Grace; Farnan, John; Black, Amy; Blighe, Kevin; Nesbit, M. Andrew; McLaughlin, James A.D.; Moore, Tara
• Is Part Of: Vaccine. Volume 40:Issue 18(2022)
• Page Start: 2535
• Page End: 2539
• Publication Date: 2022-04-20
• Subjects: COVID-19 -- SARS-CoV-2 -- Oxford-AstraZeneca ChAdOx1 -- COVID-19 vaccination -- Antibody response -- Adenovirus vector-based vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.02.087
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Background: This study evaluates spike protein IgG antibody response following Oxford-AstraZeneca COVID-19 vaccination using the AbC-19™ lateral flow device. Methods: Plasma samples were collected from n = 111 individuals from Northern Ireland. The majority were >50 years old and/or clinically vulnerable. Samples were taken at five timepoints from pre-vaccination until 6-months post-first dose. Results: 20.3% of participants had detectable IgG responses pre-vaccination, indicating prior COVID-19. Antibodies were detected in 86.9% of participants three weeks after the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% three weeks post-second vaccine. At 6-months post-first dose, this decreased to 90.5%. At all timepoints, previously infected participants had significantly higher antibody levels than those not previously infected. Conclusion: This study demonstrates that strong anti-spike protein antibody responses are evoked in almost all individuals that receive two doses of Oxford-AstraZeneca vaccine, and which largely persist beyond six months after first vaccination.